Spero Therapeutics Inc (NASDAQ:SPRO) CEO Ankit Mahadevia sold 2,293 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $14.31, for a total transaction of $32,812.83. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Ankit Mahadevia also recently made the following trade(s):
- On Tuesday, July 7th, Ankit Mahadevia sold 754 shares of Spero Therapeutics stock. The shares were sold at an average price of $14.25, for a total transaction of $10,744.50.
SPRO stock opened at $13.61 on Friday. Spero Therapeutics Inc has a 52 week low of $5.25 and a 52 week high of $14.48. The company has a quick ratio of 4.31, a current ratio of 4.31 and a debt-to-equity ratio of 0.05. The firm has a 50-day simple moving average of $12.90 and a 200-day simple moving average of $10.15. The stock has a market capitalization of $290.80 million, a P/E ratio of -3.22 and a beta of 1.97.
Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Friday, May 8th. The company reported ($1.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.35) by $0.13. Spero Therapeutics had a negative return on equity of 88.22% and a negative net margin of 654.03%. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $3.36 million. On average, analysts expect that Spero Therapeutics Inc will post -4.15 earnings per share for the current year.
A number of research analysts have weighed in on SPRO shares. Oppenheimer began coverage on shares of Spero Therapeutics in a report on Friday, May 8th. They issued a “buy” rating and a $20.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $28.00 target price on shares of Spero Therapeutics in a research report on Tuesday, June 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a report on Tuesday, March 17th. Stifel Nicolaus lowered their price target on Spero Therapeutics from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Finally, Zacks Investment Research cut Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, June 5th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Spero Therapeutics has an average rating of “Buy” and an average price target of $21.00.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its stake in shares of Spero Therapeutics by 33.5% in the first quarter. State Street Corp now owns 278,443 shares of the company’s stock worth $2,250,000 after acquiring an additional 69,852 shares during the last quarter. VR Adviser LLC purchased a new position in Spero Therapeutics in the 1st quarter valued at $3,830,000. Squarepoint Ops LLC boosted its stake in Spero Therapeutics by 13.3% during the 1st quarter. Squarepoint Ops LLC now owns 20,389 shares of the company’s stock worth $165,000 after purchasing an additional 2,386 shares during the last quarter. DAFNA Capital Management LLC purchased a new stake in shares of Spero Therapeutics during the first quarter worth $389,000. Finally, Rock Springs Capital Management LP grew its holdings in shares of Spero Therapeutics by 15.2% during the first quarter. Rock Springs Capital Management LP now owns 605,000 shares of the company’s stock worth $4,888,000 after buying an additional 80,000 shares in the last quarter. Institutional investors and hedge funds own 52.88% of the company’s stock.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease.
Featured Story: Back-End Load
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.